Well Foxwood, you've made some good points in this post.
I believe there to be a niche market for 'Nicosan', or at least there was at a certain point in time, insofar as investors were concerned.
The reason I say it's a niche market, is at least two-fold. The natural immunity to Malaria, built up through evolutionary processes in the indigenous people of Nigeria is the best way (sans DDT) to control, not eradicate Malaria. This very same process is what's responsible genetically for SCD.
Having a 'treatment' for analgesic effect by changing the shape of the sickeled cell is an excellent idea, and doesn't interfere with the natural evolutionary process already underway. As we all know, Evolutionary biology moves slower than than a politician admitting they were wrong. Malaria is a greater concern to the people of Africa, than is SCD. That is a statement of fact. Curing 'SCD' may well not be desirable, if it impinges upon what nature is already doing. This I believe is Nicosan's trump card.
Having not proven that Nicosan works as advertised to the satisfaction of the scientific community, is where XKEM (whomever you want to point a finger at) dropped the ball.
The people of Nigeria know full well that they can still go to their local healer, and get a de facto Nicosan at a fraction of the cost. This is also where XKEM (whomever you want to point a finger at) dropped the ball.
I see no hope for XKEM shareholders to recover their money, not any. I do see a possibility, if Pandey were to regain control, where the old shareholders could invest in a new company and perhaps recover some of their losses.
It should be noted that this same method can be applied to many stocks out there, so an investment in a new 'XKEM' under Pandey, is certainly not a prerequisite for getting one's money back.
I don't like Monty blending the line between humanitarian effort, and an investment. To me, that's reprehensible.
My 2¢
Fight what? I don't see anything to fight
You should see when I ignite the aft port :)
AI
